ATE394140T1 - Verwendung neuer etonogestrelester - Google Patents

Verwendung neuer etonogestrelester

Info

Publication number
ATE394140T1
ATE394140T1 AT03755980T AT03755980T ATE394140T1 AT E394140 T1 ATE394140 T1 AT E394140T1 AT 03755980 T AT03755980 T AT 03755980T AT 03755980 T AT03755980 T AT 03755980T AT E394140 T1 ATE394140 T1 AT E394140T1
Authority
AT
Austria
Prior art keywords
relesters
etonogest
new
new etonogest
etonogest relesters
Prior art date
Application number
AT03755980T
Other languages
English (en)
Inventor
Nijs Henrik De
Der Voort Hendrikus Adrian Van
Dirk Leysen
Arij Jan Grootenhuis
Der Louw Jaap Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE394140T1 publication Critical patent/ATE394140T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT03755980T 2002-05-30 2003-05-22 Verwendung neuer etonogestrelester ATE394140T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30

Publications (1)

Publication Number Publication Date
ATE394140T1 true ATE394140T1 (de) 2008-05-15

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03755980T ATE394140T1 (de) 2002-05-30 2003-05-22 Verwendung neuer etonogestrelester

Country Status (27)

Country Link
US (1) US20050222114A1 (de)
EP (1) EP1513588B1 (de)
JP (1) JP2005532336A (de)
KR (1) KR20050005507A (de)
CN (1) CN1655848A (de)
AR (1) AR040129A1 (de)
AT (1) ATE394140T1 (de)
AU (1) AU2003246740B2 (de)
BR (1) BR0311248A (de)
CA (1) CA2487293A1 (de)
DE (1) DE60320786D1 (de)
ES (1) ES2305498T3 (de)
HK (1) HK1072568A1 (de)
HR (1) HRP20041127A2 (de)
IL (1) IL165125A0 (de)
IS (1) IS7537A (de)
MX (1) MXPA04011798A (de)
NO (1) NO20044903L (de)
NZ (1) NZ536618A (de)
PE (1) PE20040042A1 (de)
PL (1) PL373295A1 (de)
RS (1) RS101004A (de)
RU (1) RU2322986C2 (de)
TW (1) TW200400041A (de)
UA (1) UA80703C2 (de)
WO (1) WO2003101374A2 (de)
ZA (1) ZA200409498B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
BR112020007673A2 (pt) * 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
WO2021252761A2 (en) * 2020-06-11 2021-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
BR9408457A (pt) * 1993-12-27 1997-08-05 Akzo Nobel Nv Preparação farmacêutica percutânia
AU6614096A (en) * 1995-07-17 1997-02-18 Schering Aktiengesellschaft Agent, for transdermal application, containing esters of 3-ketodesogestrel
AU4513099A (en) * 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
WO1999067271A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Also Published As

Publication number Publication date
CA2487293A1 (en) 2003-12-11
EP1513588B1 (de) 2008-05-07
DE60320786D1 (de) 2008-06-19
PE20040042A1 (es) 2004-01-31
NO20044903L (no) 2005-02-25
ZA200409498B (en) 2006-05-31
CN1655848A (zh) 2005-08-17
IS7537A (is) 2004-11-18
ES2305498T3 (es) 2008-11-01
PL373295A1 (en) 2005-08-22
HK1072568A1 (en) 2005-09-02
RU2322986C2 (ru) 2008-04-27
KR20050005507A (ko) 2005-01-13
IL165125A0 (en) 2005-12-18
BR0311248A (pt) 2005-03-15
AR040129A1 (es) 2005-03-16
TW200400041A (en) 2004-01-01
US20050222114A1 (en) 2005-10-06
HRP20041127A2 (en) 2005-02-28
NZ536618A (en) 2007-06-29
AU2003246740B2 (en) 2009-01-08
JP2005532336A (ja) 2005-10-27
UA80703C2 (en) 2007-10-25
WO2003101374A3 (en) 2004-02-26
MXPA04011798A (es) 2005-03-31
RS101004A (en) 2006-10-27
EP1513588A2 (de) 2005-03-16
WO2003101374A2 (en) 2003-12-11
RU2004138809A (ru) 2005-06-10
AU2003246740A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
IS7471A (is) Ný efnasambönd
IS7879A (is) Ný efnasambönd
DK1472255T3 (da) Aza-arylpiperaziner
IS7793A (is) Nýtt efnasamband
IS7827A (is) Ný efnasambönd
IS7794A (is) Nýtt efnasamband
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
NO20044293L (no) Nedihulls-gjenvinningsverktoy
ATE394140T1 (de) Verwendung neuer etonogestrelester
NO20044140D0 (no) New Composition
ITMI20021329A1 (it) Nuove ossialchilammine sostituite
ITMI20021327A1 (it) Nuove ossialchilpiperazine
UA6746S (uk) Кобза чотириструнна
ATA16732003A (de) Verwendung von brechweinstein
SE0202963D0 (sv) New use
SE0201942D0 (sv) New use
SE0202837D0 (sv) New use
SE0201152D0 (sv) New use
SE0201941D0 (sv) New use
SE0203122D0 (sv) New Compounds
SE0200523D0 (sv) New compounds
SE0202181D0 (sv) New compounds
SE0203751D0 (sv) New Compounds
SE0201925D0 (sv) New compounds
SE0202908D0 (sv) New compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties